Biologization of collagen-based biomaterials using liquid-platelet-rich fibrin: New insights into clinically applicable tissue engineering

Platelet-rich fibrin (PRF) is a blood concentrate derived from venous blood that is processed without anticoagulants by a one-step centrifugation process. This three-dimensional scaffold contains inflammatory cells and p
Platelet-rich fibrin (PRF) is a blood concentrate derived from venous blood that is processed without anticoagulants by a one-step centrifugation process. This three-dimensional scaffold contains inflammatory cells and plasma proteins entrapped in a fibrin matrix. Liquid-PRF was developed based on the previously described low-speed centrifuge concept (LSCC), which allowed the introduction of a liquid-PRF formulation of fibrinogen and thrombin prior to its conversion to fibrin. Liquid-PRF was introduced to meet the clinical demand for combination with biomaterials in a clinically applicable and easy-to-use way. The aim of the present study was to evaluate, ex vivo, the interaction of the liquid-PRF constituents with five different collagen biomaterials by histological analyses. The results first demonstrated that large variability existed between the biomaterials investigated. Liquid-PRF was able to completely invade Mucograft® (MG; Geistlich Biomaterials, Wolhusen, Switzerland) and to partly invade Bio-Gide® (BG; Geistlich Biomaterials, Wolhusen, Switzerland) and Mucoderm® (MD; Botiss Biomaterials, Berlin, Germany), and Collprotect® (CP; Botiss Biomaterials, Berlin, Germany) showed only a superficial interaction. The BEGO® collagen membrane (BCM; BEGO Implant Systems) appeared to be completely free of liquid-PRF. These results were confirmed by the different cellular penetration and liquid-PRF absorption coefficient (PAC) values of the evaluated membranes. The present study demonstrates a system for loading biomaterials with a complex autologous cell system (liquid-PRF) in a relatively short period of time and in a clinically relevant manner. The combination of biomaterials with liquid-PRF may be clinically utilized to enhance the bioactivity of collagen-based biomaterials and may act as a biomaterial-based growth factor delivery system.
show moreshow less

Metadaten
Author:Sarah al- Maawi, Carlos Herrera-Vizcaíno, Anna Orlowska, Ines Willershausen, Robert Alexander Sader, Richard J. Miron, Joseph Choukroun, Shahram Ghanaati
URN:urn:nbn:de:hebis:30:3-527441
DOI:http://dx.doi.org/10.3390/ma12233993
ISSN:1996-1944
Pubmed Id:http://www.ncbi.nlm.nih.gov/pubmed?term=31810182
Parent Title (English):Materials
Publisher:MDPI
Place of publication:Basel
Document Type:Article
Language:English
Year of Completion:2019
Date of first Publication:2019/12/02
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2020/02/17
Tag:LSCC; centrifugation; collagen; leukocytes; liquid-PRF; platelet-rich fibrin; platelets; tissue engineering
Volume:12
Issue:23, Art. 3993
Pagenumber:17
First Page:1
Last Page:17
Note:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
HeBIS PPN:461423022
Institutes:Medizin
Dewey Decimal Classification:610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Open-Access-Publikationsfonds:Medizin
Licence (German):License LogoCreative Commons - Namensnennung 4.0

$Rev: 11761 $